Amphetamine Stimulant Prodrug denied for failing step therapy by Cigna?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Amphetamine Stimulant Prodrug
## Why Cigna's Step-Therapy Protocol Triggered This Denial
Cigna uses step-therapy (also called "fail-first") requirements for amphetamine-class stimulant prodrugs, meaning the plan requires evidence that the patient has already tried one or more preferred or lower-cost stimulant medications before the requested drug will be covered. This denial is common when the prescriber writes for a newer, branded, or extended-release formulation and Cigna's system has no record of a prior trial of a step-required alternative.
## Your Appeal Rights — Including Step-Therapy Exception Laws
Step-therapy denials are among the most appealable coverage decisions. Many states have enacted step-therapy exception laws requiring insurers to grant an exception when the required step-through drug is contraindicated, previously failed, or would cause harm — and without requiring patients to re-fail a drug they have already failed. At the federal level, ACA §2719 and ERISA §503 guarantee full-and-fair internal review and independent external review. The external-review window is generally open for approximately four months after a final internal denial. Expedited review is available in urgent situations.
## Appeal Process and Timeline
1. Obtain the denial letter identifying which step-therapy requirements were not met. 2. Check your state's step-therapy exception law — your state insurance commissioner's website will list applicable protections. 3. File the internal appeal within Cigna's deadline (typically 180 days). Cigna must respond within 30 days (pre-service) or 60 days (post-service). 4. If internal appeal fails, request external review. 5. Request expedited review if your condition creates urgency.
## Documentation to Gather
- Prior trial history: A dated, medication-by-medication list of every stimulant previously tried, including start date, end date, dose range, and documented reason for failure or discontinuation (inadequate efficacy, intolerance, adverse effect).
- Medical records: Office notes and pharmacy records corroborating the prior trial history.
- Clinical rationale for skipping a step: If a required step drug was never tried because it was clinically contraindicated or inappropriate for this patient, the prescriber must document that judgment in writing.
- Prescriber medical-necessity letter: Explains why the requested drug — rather than a step-required alternative — is medically necessary for this specific patient.
- Cigna's step-therapy policy: Download the current policy and identify each required step and each recognized exception category.
## Criteria-Mapping Structure
List each step required by Cigna's policy in the left column. In the right column, document either (a) the prior trial that fulfills that step, with dates and outcome, or (b) the clinical reason the step is inapplicable to this patient. If the patient has already failed the required steps, this table is often sufficient to compel approval. If steps were skipped for clinical reasons, the prescriber's letter is the key exhibit.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →Related appeal guides
- Aetna denied for failing step therapy of Amphetamine Stimulant Prodrug
- Blue Cross Blue Shield denied for failing step therapy of Amphetamine Stimulant Prodrug
- Humana denied for failing step therapy of Amphetamine Stimulant Prodrug
- UnitedHealthcare denied for failing step therapy of Amphetamine Stimulant Prodrug